Response to Gungor et al. Regarding Morishita et al., “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan”
Pharmacoepidemiology and Drug Safety · 2026-11 · 35 (11)
DOI: 10.1002/pds.70524 ↗Abstract
Key Points This response provides additional agent‐specific exposure and outcome data for all quinolone agents included in our original study in response to the comment by Gungor et al. Moxifloxacin, garenoxacin, ofloxacin, tosufloxacin, and norfloxacin exhibited crude prevalence of MCMs that were numerically higher than the prevalence for all quinolone agents combined. We added exact 95% CIs to indicate the precision of these estimates. Reliable comparisons between individual quinolone agents were not possible because the analyses were descriptive and unadjusted, and several estimates were based on small numbers of exposures or outcomes. Therefore, these findings should be interpreted as hypothesis‐generating.
EUVIMED